Browse studies

Find your next paid study

42 recruiting studies matching your filters

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or…

Cancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more

Estimated

~$10 – $1,125

Dana-Farber Cancer InstituteNCT05463796

Phase 1

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in pati…

Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-muscle Invasive Bladder Cancer

Estimated

~$10 – $8,750

enGene, Inc.NCT04752722

Phase 2

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese w…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06195306

Phase 2

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. In…

Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast Carcinoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06184750

Phase 1

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle in…

Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more

Estimated

~$10 – $8,750

UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.NCT07725796

Observational

Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes

This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testi…

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeBreast Ductal Carcinoma In SituHematopoietic and Lymphoid System Neoplasm+3 more

Estimated

~$10 – $7,500

OHSU Knight Cancer InstituteNCT04494945

Phase 2

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing…

Breast Atypical HyperplasiaBreast CarcinomaBreast Ductal Carcinoma In Situ+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05941520

Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute

This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identif…

Breast Atypical Ductal HyperplasiaBreast Atypical Lobular HyperplasiaBreast Carcinoma+2 more

Estimated

~$10 – $750

Ohio State University Comprehensive Cancer CenterNCT05178498

Phase 2

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary…

Ductal Carcinoma in Situ

Estimated

~$10 – $6,250

University of FloridaNCT06868238

Phase 2

Intravesical Gemcitabine and Docetaxel for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study (GEMDOCE-BU)

The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasiv…

Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more

Estimated

~$10 – $7,500

Michael A. O'DonnellNCT07322263

Phase 2

A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia

This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab,…

Cervical Intraepithelial NeoplasiaCervical Squamous Cell Carcinoma In SituCervical Squamous Intraepithelial Neoplasia 2

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT04712851

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy

This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions…

DCISStage 0 Breast CancerDuctal Breast Carcinoma In Situ

Estimated

~$10 – $1,125

PreludeDxNCT03448926